188 related articles for article (PubMed ID: 32641858)
1. p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth.
Ouyang H; Luong P; Frödin M; Hansen SH
Oncogene; 2020 Aug; 39(33):5570-5587. PubMed ID: 32641858
[TBL] [Abstract][Full Text] [Related]
2. p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity.
Frank SR; Köllmann CP; Luong P; Galli GG; Zou L; Bernards A; Getz G; Calogero RA; Frödin M; Hansen SH
J Cell Biol; 2018 Sep; 217(9):3183-3201. PubMed ID: 29934311
[No Abstract] [Full Text] [Related]
3. p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor suppressor function mediated by p190A RhoGAP.
Ouyang H; Li W; Hansen SH
bioRxiv; 2023 May; ():. PubMed ID: 37292741
[No Abstract] [Full Text] [Related]
4. p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP.
Ouyang H; Wu S; Li W; Grey MJ; Wu W; Hansen SH
Cell Rep; 2023 Dec; 42(12):113486. PubMed ID: 37995182
[TBL] [Abstract][Full Text] [Related]
5. p190A inactivating mutations cause aberrant RhoA activation and promote malignant transformation via the Hippo-YAP pathway in endometrial cancer.
Wen X; Wan J; He Q; Wang M; Li S; Jiang M; Qian Z; Liu B; Lu W; Wang K; Gao K; Wan X
Signal Transduct Target Ther; 2020 May; 5(1):81. PubMed ID: 32457342
[TBL] [Abstract][Full Text] [Related]
6. Rho-kinase contributes to sustained RhoA activation through phosphorylation of p190A RhoGAP.
Mori K; Amano M; Takefuji M; Kato K; Morita Y; Nishioka T; Matsuura Y; Murohara T; Kaibuchi K
J Biol Chem; 2009 Feb; 284(8):5067-76. PubMed ID: 19103606
[TBL] [Abstract][Full Text] [Related]
7. Hippo signaling is intrinsically regulated during cell cycle progression by APC/C
Kim W; Cho YS; Wang X; Park O; Ma X; Kim H; Gan W; Jho EH; Cha B; Jeung YJ; Zhang L; Gao B; Wei W; Jiang J; Chung KS; Yang Y
Proc Natl Acad Sci U S A; 2019 May; 116(19):9423-9432. PubMed ID: 31000600
[TBL] [Abstract][Full Text] [Related]
8. A Ca
Dang DK; Makena MR; Llongueras JP; Prasad H; Ko M; Bandral M; Rao R
Mol Cancer Res; 2019 Aug; 17(8):1735-1747. PubMed ID: 31076498
[TBL] [Abstract][Full Text] [Related]
9. Interaction of p190A RhoGAP with eIF3A and Other Translation Preinitiation Factors Suggests a Role in Protein Biosynthesis.
Parasuraman P; Mulligan P; Walker JA; Li B; Boukhali M; Haas W; Bernards A
J Biol Chem; 2017 Feb; 292(7):2679-2689. PubMed ID: 28007963
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated mutations in the protrusion-targeting region of p190RhoGAP impact tumor cell migration.
Binamé F; Bidaud-Meynard A; Magnan L; Piquet L; Montibus B; Chabadel A; Saltel F; Lagrée V; Moreau V
J Cell Biol; 2016 Sep; 214(7):859-73. PubMed ID: 27646271
[TBL] [Abstract][Full Text] [Related]
11. Induction of entosis by epithelial cadherin expression.
Sun Q; Cibas ES; Huang H; Hodgson L; Overholtzer M
Cell Res; 2014 Nov; 24(11):1288-98. PubMed ID: 25342558
[TBL] [Abstract][Full Text] [Related]
12. TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity.
Lee Y; Ko D; Yoon J; Lee Y; Kim S
J Exp Clin Cancer Res; 2021 Mar; 40(1):58. PubMed ID: 33641663
[TBL] [Abstract][Full Text] [Related]
13. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
14. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
15. Hippo kinases regulate cell junctions to inhibit tumor metastasis in response to oxidative stress.
Wang Y; Li J; Gao Y; Luo Y; Luo H; Wang L; Yi Y; Yuan Z; Jim Xiao ZX
Redox Biol; 2019 Sep; 26():101233. PubMed ID: 31212215
[TBL] [Abstract][Full Text] [Related]
16. The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.
He Y; Northey JJ; Pelletier A; Kos Z; Meunier L; Haibe-Kains B; Mes-Masson AM; Côté JF; Siegel PM; Lamarche-Vane N
Oncogene; 2017 Jun; 36(24):3490-3503. PubMed ID: 28135249
[TBL] [Abstract][Full Text] [Related]
17. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
[TBL] [Abstract][Full Text] [Related]
18. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
[TBL] [Abstract][Full Text] [Related]
19. Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition.
Sun Y; Du R; Shang Y; Liu C; Zheng L; Sun R; Wang Y; Lu G
Bioengineered; 2022 Jun; 13(6):14605-14615. PubMed ID: 35758029
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components.
Kim NG; Koh E; Chen X; Gumbiner BM
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11930-5. PubMed ID: 21730131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
